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Abstract 
Objective: Thiazolidinediones (TZDs) are putatively transported into the liver by OATP1B1 
(encoded by SLCO1B1) and metabolized by CYP450 2C8 enzyme (encoded by CYP2C8). 
Whilst CYP2C8*3 has been shown to alter TZD pharmacokinetics, it has not been shown to 
alter efficacy.  
 
Design: We genotyped 833 Scottish Type 2 diabetes patients treated with pioglitazone or 
rosiglitazone and jointly investigated association of variants in these two genes with therapeutic 
outcome. 
 
Result: The CYP2C8*3 variant was associated with reduced glycaemic response to 
rosiglitazone (P = 0.01) and less weight gain (P = 0.02). The SLCO1B1 521T>C variant was 
associated with enhanced glycaemic response to rosiglitazone (P = 0.04). The super responders 
defined by combined genotypes at CYP2C8 and SLCO1B1 had a 0.39% (4 mmol/mol) greater 
HbA1c reduction (P = 0.006) than the poor responders. Neither of the variants had a significant 
impact on pioglitazone response. 
 
Conclusion: These results show that variants in CYP2C8 and SLCO1B1 have a large clinical 
impact on the therapeutic response to rosiglitazone, and highlight the importance of studying 
transporter and metabolising genes together in pharmacogenetics. 
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The TZDs, pioglitazone and rosiglitazone, have been widely used in combination with other 
oral agents for the treatment of type 2 diabetes. They act as peripheral insulin sensitizers by 
activating the nuclear peroxisome proliferator-activated receptor-γ (PPARG), which regulates 
the transcription of genes related to glucose metabolism (1). Following a meta-analysis of 42 
studies that linked rosiglitazone to an increased risk of cardiovascular adverse effects (2), its 
marketing authorisation was withdrawn in Europe, and restricted use in the US. However its 
restriction has been lifted after the RECORD study failed to show cardiac risks associated with 
rosiglitazone (3). Pioglitazone is still in clinical use in most countries and its use has been 
suspended in France, and restricted in Germany, due to a small absolute increased risk in 
bladder cancer. However a recent multi-population analysis showed no association of 
pioglitazone or rosiglitazone with the risk of bladder cancer (4).  
 
TZDs are effective at lowering HbA1c by about 1~1.25% (11-14mmol/mol) on average (5). 
Although TZDs show durability in action greater than seen with either metformin or 
sulphonylureas (6), weight gain induced by TZDs has restrained their clinical utility (7). For 
every 1% reduction in HbA1c an estimated 2-3% weight gain is documented (1). 
 
The American Diabetes Association (ADA) and European Association for the Study of 
Diabetes (EASD) guidelines continue to highlight the need to individualise treatment in 
diabetes (8), and this applies particularly for the TZDs where substantial inter-individual 
variation exists in glycaemic response (9). Epidemiological studies have identified age, gender, 
baseline weight and HbA1c as significant predictors of response, which can account for up to 
49% of the variation in HbA1c reduction (10, 11). Genetic factors are expected to explain at 
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least part of the remaining variation and may be important to better aid targeted treatment in 
this patient group. 
 
In-silico modelling has shown that both pioglitazone and rosiglitazone are putative substrates 
of transporter OATP1B1 which is encoded by SLCO1B1 (12). Both agents are extensively 
metabolized in the liver, mainly by the cytochrome P450 2C8 enzyme encoded by CYP2C8 
(13, 14). The main metabolites of rosiglitazone are N-desmethyl-rosiglitazone and 
rosiglitazone-para-O-sulfate that are 20-55 fold less potent compared to the parent drug (15). 
The principal metabolites of pioglitazone are M-III and M–IV; in contrast to the metabolites 
of rosiglitazone, they are shown to be pharmacologically active (16). Gemfibrozil, which 
inhibits both CYP2C8 and OATP1B1 has been shown to increase the plasma concentration 
Area Under the Curve (AUC) of pioglitazone and rosiglitazone between 2.4 and 3-fold in 
healthy volunteers (17, 18), suggesting a role for both CYP2C8 and OATP1B1 in 
pharmacokinetics of the agents. 
 
Genetic variants CYP2C8*3 (linked polymorphisms of Arg139Lys and Lys399Arg), and 
SLCO1B1 521 T>C (Val174Ala) are commonly seen in populations of European ancestry with 
allele frequencies at around 12% and 16%, respectively (19).  Pharmacokinetic studies of 
healthy volunteers have established that the gain of function CYP2C8*3 variant is associated 
with modestly enhanced TZD metabolism. Homozygote CYP2C8*3 carriers had 36% lower 
rosiglitazone plasma concentration and 39% higher weight-adjusted oral clearance rate 
compared to the wild type carriers, with clear gene dosage effect seen in the heterozygotes (20, 
21). A similar trend has been shown with pioglitazone (22). Despite the pharmacokinetic effect 
of CYP2C8 variant on rosiglitazone, the studies that have assessed its impact on rosiglitazone 
efficacy have found no associations in small number of healthy non-insulin resistant volunteers 
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(20, 21). For SLCO1B1, despite the in-silico modelling, a pharmacokinetic study of 32 healthy 
volunteers found no association between the loss of function 521C allele and weight-adjusted 
plasma drug AUC after single dose rosiglitazone (4mg) or pioglitazone administration (23). 
The lack of consistency of these pharmacokinetic and dynamic studies is potentially due to the 
limited statistical power in the small samples to detect the moderate genetic effect, and the fact 
that the variants have previously been considered in isolation.   
 
As TZDs have to be transported into the liver to be metabolised by CYP2C8, we assessed the 
glycaemic response and side effect of weight gain induced by variants in SLCO1B1 and 
CYP2C8 together in a large population of patients with Type 2 diabetes treated with 
rosiglitazone or pioglitazone. 
 
Research design and Methods 
Sample ascertainment 
Patients were ascertained from the Diabetes Audit and Research Tayside Study (DARTS), 
which has been described in detail previously (24).  In brief, all the patients can be linked to 
the Medicine Monitoring Unit/Health Informatics Centre Database to retrieve validated 
prescribing, and to the clinical information system SCI-DC to obtain all biochemistry and 
clinical phenotypic data back to 1992. Prospective longitudinal data were also collected on 
these patients.  Since October 1997, all patients with diabetes have been invited to give written 
informed consent to DNA and serum collection as part of the Wellcome Trust United Kingdom 
Type 2 Diabetes case control collection. As of June 2009, more than 9000 patients have 
participated in this Genetics of DARTS (Go-DARTS) study. 
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From 1942 incident TZD users in the Go-DARTS cohort, we identified a study sample of 833 
patients who had TZD as their second-line (added to metformin or sulfonylurea monotherapy) 
or third-line (added to metformin and sulfonylurea dual therapy) treatment according to 
guideline in Scotland. To be included in the study, individuals had to have complete data with 
respect to age, gender, weight, oral antidiabetic treatment history, TZD treatment dose, 
adherence and regular HbA1c measurements. They all had a baseline HbA1c higher than 7%. 
They were on stable treatment for at least 6 months after TZD was initiated (the index date), 
which meant they did not start or stop another antidiabetic drug within 6 months either side of 
the TZD index date. They were not treated with insulin before or during the studied period. 
This will help to ascertain TZDs related efficacy outcomes. A detailed sample ascertainment 
procedure is outlined in Supplemental Figure 1. The study was approved by the Tayside 
Regional Ethics Committee and informed consent was obtained from all subjects. 
 
Drug response definitions 
Individuals’ glycaemic response to TZDs was modelled as the maximum HbA1c reduction 
recorded within 1 to 18 months of the index date while maintained on stable treatment. 
Similarly, TZD induced weight gain was measured as the difference between the last 
measurement within the study period and the baseline weight. The multivariate linear model 
equation for these two outcomes is: 
 
HbA1c Reduction (Weight Gain) ~ Baseline HbA1c + Baseline Weight + Adherence + Daily 
Dose + Study Duration + Age + Sex + Genotype 
 
Baseline HbA1c and baseline weight were defined as the nearest measures taken within the 
180 days prior to the TZD index date. Adherence was calculated from the population-based 
7 
 
drug dispensing records as the percentage of maximum possible adherence for each participant. 
Treatment dose was determined as the mean dose of prescriptions encashed during the three 
months prior to the minimum HbA1c within the 1-18 months of TZD index date. When the 
minimum HbA1c happened in less than three months, the average dose before the treatment 
HbA1c was recorded.  
 
Genotyping 
CYP2C8*3 (rs10509681) and SLCO1B1 521T>C (rs4149056) were genotyped in the entire 
Go-DARTS cohort with Taqman-based allelic discrimination assays. As the two CYP2C8*3 
variants rs10509681 and rs11572080 are in perfect linkage disequilibrium (r2 = 1 in the 1000 
genome CEU panel) (25), only rs10509681 was genotyped in the current study. Assays were 
performed under manufacturer (Applied Biosystems) recommended standard conditions. 
Assays were performed on 10ng genomic DNA in 384 well plates; cycled using a H2OBIT 
thermal cycler (Thermo Scientific, Surrey); fluorescence detection and genotype calling were 
performed on an ABI 7900FastHT sequence detection system (Applied Biosystems).  
 
Statistical analysis 
One-way ANOVA was used to test for differences in the baseline characteristics by genotype. 
Allele frequencies difference between subgroups and the full sample was compared in a 2d.f. 
Chi-Squared test. The exact test of Hardy-Weinberg Equilibrium was carried out with PLINK 
(26). Multivariate linear regression analyses of HbA1c reduction and weight gain were 
performed with PLINK under additive genetic model and all the covariates included.  
 
Results 
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In the 833 patients studied, the allele frequencies of CYP2C8*3 and SLCO1B1 521 C were 
14.5% and 16%, respectively. The overall genotyping call rate was 94% and both SNPs were 
in Hardy-Weinberg Equilibrium in the sample (P > 0.05). In addition we compared the Taqman 
genotypes to the existing genotypes from exomechip and the concordance rate for rs10509681 
and rs4149056 were 99.8% and 99.7%, respectively. There was no baseline clinical 
characteristic difference according to CYP2C8 or SLCO1B1 variant genotypes (Supplemental 
Table S1). 
 
The number of patients treated with pioglitazone and rosiglitazone were 273 and 519 
respectively, with the other 41 patients switched between the two agents. In the combined 
analysis higher baseline HbA1c, higher baseline weight, older age, being female, higher 
adherence and longer treatment duration were independently associated with better glycaemic 
response. Greater weight gain was associated with higher baseline HbA1c, higher baseline 
weight, higher daily dose, being female and being treated by pioglitazone. No significant 
association with HbA1c reduction was observed when the CYP2C8*3 and SLCO1B1 521C 
variants were included into the clinical model (Supplemental Table S2). However compared to 
the wild type, carriers of the *3 allele had less weight gain (β= -0.91, P = 0.006).   
 
Compared to parent drugs, metabolites of rosiglitazone and pioglitazone exert different degrees 
of glycaemic efficacy (16). In addition, differences in baseline characteristics of pioglitazone 
and rosiglitazone treated individuals, as shown in Supplemental Table S3 have been observed. 
Therefore we performed multiple linear regression analysis in the two subgroups separately. 
The same set of clinical covariates were included in the modelling of weight gain and HbA1c 
reduction. Table 1 shows the full clinical models in rosiglitazone treated group. A higher 
baseline HbA1c, higher baseline weight, older age, being female and longer treatment were all 
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independently associated with better glycaemic response. A higher daily dose was the only 
strong predictor of weight gain with patients on 8mg/day gaining 2kg more weight than those 
on 4kg/day (although dose was not associated with glycaemic response to rosiglitazone). For 
pioglitazone treated patients, a similar pattern of clinical predictors were observed but with less 
statistical significance due to the smaller number of patients (Supplemental Table S4). In 
contrast to rosiglitazone, there was no significant effect of pioglitazone dose on weight gain.  
 
When genetic variants were added to the clinical models, patients carrying the CYP2C8*3 
variant achieved less HbA1c reduction (allelic beta = -0.21%, P = 0.01) and experienced less 
weight gain (allelic beta = -0.93kg, P = 0.02) with rosiglitazone treatment. The SLCO1B1 521C 
variant was associated with greater HbA1c reduction (allelic beta= 0.18%, P = 0.04), but not 
weight gain after rosiglitazone treatment. Neither of the two variants was significantly 
associated with response to pioglitazone (see Table 2). This could be due to lack of enough 
statistical power from smaller number of patients treated with pioglitazone. Assuming the *3 
variant has the same allelic effect size of 0.21% HbA1c reduction on both rosiglitazone and 
pioglitazone, the current sample size of 273 pioglitazone users will provide only 37% statistical 
power to detect the association at an alpha level of 0.05 (27). More than 800 samples are 
required to provide sufficient (80%) statistical power to detect such an effect size. 
 
To better assess the impact of these variants in rosiglitazone response, we considered a 
composite model consisting a group of super responders (reduced transport at OATP1B1 
(SLCO1B1 521 C) and ‘normal’ metabolisers at CYP2C8 (wild type)), intermediate responders 
(wild type at CYP2C8 and SLCO1B1) and poor responders (‘normal’ transport of rosiglitazone 
into the liver across OATP1B1 (SLCO1B1 521 T) and increased metabolism by CYP2C8 
(CYP2C8*3)). When the two variants were considered together, as shown in Figure 1, the super 
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responders had a 0.39% (4 mmol/mol) (P = 0.006) greater HbA1c reduction than  the poor 
responders. A similar, but non-significant effect was seen on weight gain.  
 
Since dosing is a strong predictor of rosiglitazone induced weight gain, we performed a 
stratified genetic analysis of the rosiglitazone treated patients by daily dose.  As shown in 
Supplemental Table S5, the CYP2C8*3 variant had a similar impact on weight gain and HbA1c 
reduction in those treated with 4mg/day and 8mg/day. The SLCO1B1 variant had a stronger 
impact on glycaemic response in those treated with 8mg/day than those treated with 4mg/day. 
Due to the limited sample size, this observed pharmacogenetic difference is not statistically 
significant in a formal gene by dose interaction test (P = 0.73).  
 
Conclusion 
In this large population pharmacogenetic study of patients with type 2 diabetes, we have jointly 
investigated whether variants in the putative drug transporter gene SLCO1B1 and the 
metabolizing enzyme gene CYP2C8 contribute to variation in glycaemic response and weight 
gain in response to treatment with TZDs. We confirm previous reports that TZDs work better 
in women, and with increasing obesity (28, 29).  The combined genotypes at CYP2C8 and 
SLCO1B1 can be used to define a super response and a poor response groups to rosiglitazone, 
who differ in HbA1c reduction by approximately 0.39% (4 mmol/mol). This effect size is about 
one-third of the average HbA1c reduction achieved by 8mg daily rosiglitazone (5) or about 
half of the HbA1c reduction related to DPP-4 inhibitors monotherapy (30). Therefore, the effect 
size observed in this study could be clinically relevant in stratified medicine. On the other hand 
these variants do not alter pioglitazone response. 
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We showed rosiglitazone treated individuals carrying the CYP2C8*3 variant had poorer 
glycaemic response but less weight gain in a gene-dosage dependent manner compared to the 
wild type carriers. These results are consistent with previous pharmacokinetic studies which 
showed that the CYP2C8*3 variant was associated with higher rosiglitazone oral clearance, 
and lower plasma concentration AUC (20, 21). Other previous investigations into the 
pharmacodynamic impact of CYP2C8 variations on rosiglitazone response have found no 
evidence in small samples of normal insulin sensitivity subjects (20, 21). However association 
of the CYP2C8*3 variant with impaired HbA1c lowering has been reported in type 2 diabetes 
individuals (31). The current study has demonstrated that the mild pharmacokinetic difference 
between CYP2C8*3 genotype can be translated into pharmacodynamic difference in 
rosiglitazone treated type 2 diabetes individuals, with the lower drug exposure among the 
CYP2C8*3 variant carriers resulting in less HbA1c reduction and weight gain.  
 
In this study we showed association of CYP2C8*3 with response to rosiglitazone but not 
pioglitazone despite an established role of CYP2C8 in pioglitazone pharmacokinetics. This is 
entirely consistent with the contrast between the pharmacological properties of the two agents 
(Figure 2). As the main rosiglitazone metabolites are less potent, pharmacokinetic difference 
of the parent drug were translated into efficacy difference. For pioglitazone, the principal 
biotransformation products, M-III and M-IV, are reported to exert sustained hypoglycaemic 
action, therefore ameliorate the pharmacokinetic difference in parent drug on overall efficacy 
(32).  
 
In this study, we have for the first time showed that the SLCO1B1 521C allele is associated 
with better glycaemic response in patients treated with rosiglitazone. Our results also indicated 
that the pharmacogenetic effect of SLCO1B1 521 T>C variant on rosiglitazone response was 
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more pronounced in the 8mg/day group than in the 4mg/day group. This might explain why 
previous rosiglitazone pharmacokinetic studies reported no significant association between 
SLCO1B1 521 T>C genotypes and drug exposure after 4mg/day treatment and suggests the 
variant becomes rate limiting only at high doses (19, 20). 
 
Joint investigation of variants in genes encoding for proteins involved in pharmacokinetics and 
pharmacodynamics of a given drug is believed to give better understanding of the role of 
genetics in drug response than individual variants per se. For example, studies investigating 
joint effect of variants in metformin transporters has been published elsewhere (33-35). With 
this in mind, we have investigated joint effect of variants in genes encoding TZD transporter 
(SLCO1B1) and metabolizer (CYP2C8). In a composite model that consists of super responders 
and poor responders, the glycaemic effect of the SLCO1B1 variant is much greater when 
considered on a CYP2C8 wild type background (allelic effect 0.22) compared to on a CYP2C8 
variant background (allelic effect 0.1). This finding highlights the importance, when 
considering drug transporters and drug metabolizing enzymes, to assess variants that alter drug 
availability for metabolism and variants that alter rate of metabolism together, otherwise 
clinically important variants may be overlooked. Moreover, other functional variants such as 
those regulatory variants in these two genes could also affect the pharmacokinetics of TZDs, 
therefore contribute to the variation in treatment outcome. Locus-wise genetic screening would 
be useful to identify other functional variants in these two genes. In addition, further functional 
studies investigating the joint role of these variants on HbA1c reduction and weight gain are 
also warranted.   
 
There were some limitations of our study.  The main limitation is the observational nature of 
our dataset which may introduce bias.  Response modelling has shown baseline HbA1c and 
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weight, the dose given, treatment duration, age and sex all added variation to TZD response 
among the patients. Despite adjusting for these clinical characteristics in the model, the 
association between genetic variants and drug response could still be confounded.  However, 
there was no phenotypic difference by genotype in our study sample as shown in Supplemental 
Table S1, and the clinicians and participants were clearly blind to genotype, so these extrinsic 
factors will not introduce bias to the pharmacogenetic effect. A further limitation is our measure 
of weight gain. It is not possible to differentiate if measured weight gain reflects fluid retention 
or increase in fat mass or both.  Finally, our sample size, despite being much larger than any 
published study, is still small. This in particular limits the phenotypes we are able to study.  For 
example, it is not possible to assess the impact of these variants on other side effects such as 
incident heart failure due to a major lack of power.  
 
Finally we acknowledge that we have undertaken a number of statistical tests in this study.  We 
performed a total number of eight independent genetic association tests (two variants against 
two outcomes in two treatment groups) which carry a threshold of p=0.006 (0.05/8) for any 
individual signal to be study-wide significant under a stringent Bonferroni correction. As 
shown in table 2, three independent signals did reach the conventional threshold of p<0.05 with 
the current sample size.  In addition when the genotypes of the two variants were combined 
together based on known biological mechanism, a study-wide significant (p=0.006) result was 
observed between super responders and poor responders to rosiglitazone. 
 
This study established that glycaemic response and weight gain in rosiglitazone treated type 2 
diabetes individuals were associated with genetic variants in the drug transporter gene 
SLCO1B1 and the metabolizing enzyme gene CYP2C8, and highlighted the importance of 
studying pharmacokinetic genes together. The genetically defined super responders had an 
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extra 0.39% (4 mmol/mol) HbA1c reduction than those non-responders.  Whilst our results 
establish key pharmacogenetic variants that alter response to rosiglitazone, there could be 
factors that hinder its direct clinical applicability. The variants that increase glycaemic efficacy 
to rosiglitazone also increase weight gain i.e. the ‘benefit’ and ‘harm’ are both increased. With 
the increasing awareness of risk associated with TZDs there is a need to optimize the benefit 
and reduce the risk for an individual.  We believe that this is a key opportunity for 
pharmacogenetics to potentially identify individuals who can benefit from the considerable 
therapeutic advantages of TZDs, who are least at risk of the side effects.  Rather than letting 
TZDs slide into disuse, efforts should concentrate on identifying predictors of response or harm 
to TZDs.    
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Figure Legends 
Figure 1. Rosiglitazone response by SLCO1B1 and CYP2C8 genotypes. Super responders 
(wild type at CYP2C8 and one or more variant C allele at SLCO1B1), Intermediate responders 
(wild type at both CYP2C8 and SLCO1B1), Poor responders (one or more *3 allele at CYP2C8 
and wild type at SLCO1B1). The error bars represented the standard error of the mean. **P < 
0.01. 
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Figure 2. Pharmacogenetic effect of CYP2C8 and SLCO1B1 on TZDs pharmacokinetics and 
pharmacodynamics. Pharmacogenetic influence by CYP2C8 and SLCO1B1 variants is 
expected to affect rosiglitazone pharmacodynamics because both its main metabolites (N-
desmethyl-rosiglitazone and rosiglitazone-para-O-sulfate) are less potent than its parent drug 
and pharmacokinetic differences will alter the drug exposure of active components (the parent 
drug, rosiglitazone) and therefore therapeutic response. Patients carrying the wild type 
SLCO1B1 allele and gain of function CYP2C8 variants are expected to eliminate rosiglitazone 
much faster (poor responders) than carriers of the loss of function SLCO1B1 variants on a wild 
type CYP2C8 background (super responders). In comparison, no pharmacogenetic effect is 
expected on pioglitazone response as its main metabolites (M-II, M-III and M-IV) remain 
active and the exposure of total active drug components is not altered by pharmacokinetic 
difference. 
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Table 1. Multiple linear models for HbA1c reduction and weight gain in rosiglitazone. 
 Weight Gain HbA1C Reduction 
 Beta 95% CI P-value Beta 95% CI P-value 
Baseline HbA1c 0.33 [0.15,0.65] 0.04 0.65 [0.59,0.72] < 0.001 
Baseline Weight 0.23 [-0.01,0.47] 0.06 0.07 [0.02,0.13] 0.004 
Age 0.19 [-0.19,0.58] 0.33 0.23 [0.15,0.31] < 0.001 
Sex 0.82 [-0.12,1.66] 0.06 0.28 [0.09,0.46] 0.003 
Dose 0.41 [0.25,0.59] < 0.001 0.03 [-0.01,0.06] 0.19 
Adherence 0.23 [-0.06,0.51] 0.11 0.05 [-0.01,0.11] 0.09 
Study Duration -0.08 [-0.20,0.04] 0.18 0.06 [0.03,0.08] < 0.001 
Sex was coded 1 and 2 for male and female respectively; Age was coded in the unit of 10 years; Baseline 
HbA1C was measured as percentage; Dose was measured as 10% of the recommended maximum daily dose; 
Adherence was measured in 10%; Baseline weight was measured in 10kg; and the study duration was measured 
in month as the time from TZD index date to the treatment outcome measurement date. 
 
22 
 
Table 2. Genetic effect of CYP2C8 and SLCO1B1 variants on HbA1c reduction and weight 
gain (additive genetic model). 
Treatment Gene 
Weight Gain HbA1C Reduction 
Beta 95% CI P-value Beta 95% CI P-value 
Rosiglitazone 
(n=444) 
CYP2C8*3 -0.93 [-1.73,-0.13] 0.02 -0.21 [-0.38,-0.04] 0.01 
SLCO1B1 -0.13 [-0.92,0.67] 0.75 0.18 [0.01,0.34] 0.04 
Pioglitazone 
(n=239) 
CYP2C8*3 -0.46 [-1.45,0.51] 0.34 0.14 [-0.10,0.38] 0.26 
SLCO1B1 -0.02 [-0.92,0.87] 0.96 -0.10 [-0.32,0.12] 0.37 
 
 
 
 
 
 
 
 
 
 
 
 
